Dipyridamole increases VP16 growth inhibition, accumulation and retention in parental and multidrug-resistant CHO cells

British Journal of Cancer

Volumn 73, Issue 7, 1996, Pages 856-860

  Turner, R N ^a   Curtin, N J ^a  

^a NEWCASTLE UNIVERSITY   (United Kingdom)

Author keywords

Chinese hamster ovary cell; Dipyridamole; Multidrug resistance; VP16

Indexed keywords

ANTINEOPLASTIC AGENT; ANTITHROMBOCYTIC AGENT; DIPYRIDAMOLE; ETOPOSIDE; GLYCOPROTEIN P;

ANIMAL CELL; ARTICLE; BIOACCUMULATION; CELL GROWTH; CHO CELL; CONTROLLED STUDY; DOSE TIME EFFECT RELATION; DRUG POTENTIATION; DRUG RETENTION; FEMALE; GROWTH INHIBITION; MULTIDRUG RESISTANCE; NONHUMAN; PRIORITY JOURNAL;

EID: 0030010350     PISSN: 00070920     EISSN: None     Source Type: Journal    
DOI: 10.1038/bjc.1996.152     Document Type: Article

References (23)

1. ASOH K-I, YOSHIO S, SATO S-I, NOGAE I, KOHNO K AND KUWANO M. (1990). Potentiation of some anticancer agents by dipyridamole against drug-sensitive and drug-resistant cancer cell lines. Jpn. J. Cancer Res., 80, 475-481.
2. BELT JA, MARINA NM, PHELPS DA AND CRAWFORD CR. (1993). Nucleoside transport in normal and neoplastic cells. Adv. Enzyme Regul., 33, 235-252.
3. 1-acid glycoprotein in wild-type and multidrug-resistant Chinese hamster ovary cell lines. Cancer Res., 50, 2818-2822.
4. COLE SPC, BHARDWAJ G, GERLACH JH, MACKIE JE, GRANT CE, ALMQUIST KC, STEWART AJ, KURZ EU, DUNCAN AMV AND DEELEY RG. (1992). Overexpression of a transporter gene in a multidrug-resistant human lung cancer cell line. Science, 258, 1650-1654.
5. COLE SPC, SPARKS KE, FRASER K, LOE DW, GRANT CE, WILSON GM AND DEELEY RG. (1994). Pharmacological characterisation of multidrug resistant MRP-transfected human tumour cells. Cancer Res., 54, 5902-5910.
6. ENDICOTT JA AND LING V. (1989). The biochemistry of P-glycoprotein-mediated multidrug resistance. Annu. Rev. Biochem., 58, 137-171.
7. GOEL R AND HOWELL SB. (1992). Modulation of the activity of cancer chemotherapeutic agents by dipyridamole. In New Drugs, Concepts and Results in Cancer Chemotherapy, Muggia FM. (ed.) pp. 19-44. Kluwer Academic Press: Boston, MA.
8. GUPTA RS. (1988). Intrinsic multidrug resistance phenotype of Chinese hamster (rodent) cells in comparison to human cells. Biochem. Biophys. Res. Comm., 153, 598-605.
9. HOBAN PR, ROBSON CN, DAVIES SM, HALL AG, CATTAN AR, HICKSON ID AND HARRIS AL. (1992). Reduced topoisomerase II and elevated aclass glutathione S-transferase expression in a multidrug resistant CHO cell line highly cross-resistant to mitomycin C. Biochem. Pharmacol., 43, 685-693.
10. HOWELL SB, HOM D, SANGA R, VICK JS AND ABRAMSON IS. (1989a). Comparison of the synergistic potentiation of etoposide, doxorubicin and vinblastine cytotoxicity by dipyridamole. Cancer Res., 49, 3178-3183.
11. HOWELL SB, HOM D, SANGA R, VICK JS AND CHAN TKC. (1989b). Dipyridamole enhancement of etoposide sensitivity. Cancer Res., 49, 4147-4153.
12. KUBOTA N, NISHIO K, TAKEDA Y, OHMORI T, FUNAYAMA Y, OGASAWARA H, OHIRA T, KUNIKANE H, TERASHIMA Y AND SAIJO N. (1994). Characterisation of an etoposide-resistant human ovarian cancer cell line. Cancer Chemother. Pharmacol., 34, 183-190.
13. PLAGEMANN PGW, WOHLHUETER RM AND WOFFENDIN C. (1988). Nucleoside and nucleobase transport in animal cells. Biochim. Biophys. Acta., 947, 405-443.
14. POLlTI PM, ARNOLD ST, FELTSED RL AND SINHA BK. (1990). P-glycoprotein-independent mechanism of resistance to VP-16 in multidrug-resistant tumour lines: Pharmacokinetic and photo-affinity labelling studies. Mol. Pharmacol., 37, 790-796.
15. RAMU A, SPANIER R, RAHAMIMOFF H AND FUKS Z. (1984). Restoration of responsiveness in doxorubicin-resistant P388 murine leukaemia cells. Br. J. Cancer, 50, 501-507.
16. RAPPA G, LORICO A AND SARTORELLI AC. (1993). Reversal of etoposide resistance in non-p-glycoprotein expressing multidrug resistant tumour cells by novobiocin. Cancer Res. 53, 5487-5493.
17. SCHMOLL H-J, HARSTRICK A, KOHNE-WOMPNER C-H, SCHOBER C, WILKE H AND POLIWODA H. (1990). Modulation of cytotoxic drug activity by dipyridamole. Cancer Treat. Rev., 17, (suppl. A) 57-65.
18. SCHNEIDER E, HORTON JK, YANG C-H, NAKAGAWA N AND COWAN KH. (1994). Multidrug resistance-associated protein gene overexpression and reduced drug sensitivity of topoisomerase 11 in a human breast carcinoma MCF7 cell line selected for etoposide resistance. Cancer Res., 54, 152-158.
19. SEHESTED M, FRICHE E, JENSEN PB AND DEMANT EJF. (1992). Relationship of VP-16 to the classical multidrug resistance phenotype. Cancer Res., 52, 2874-2879.
20. SHALINSKY DR, ANDREEFF M AND HOWELL SB. (1990). Modulation of drug sensitivity by dipyridamole in multidrug resistant tumour cells in vitro. Cancer Res., 50, 7537-7543.
21. SKEHAN P, STORENG R, SCUDIERO D, MONKS A, MCMAHON J, VISTICA D, WARREN JT, BOKESCH H, KENNEY S AND BOYD MR. (1990). New colorimetric cytotoxicity assay for anticancer-drug screening. J. Natl Cancer Inst., 82, 1107-1112.
22. SOUES S, LAVAL F AND CHARCOSSET J-Y. (1995). Mechanism of resistance to combinations of vincristine, etoposide and doxorubicin in Chinese hamster ovary cells. Br. J. Cancer, 71, 489-497.
23. WIGLER PW AND PATTERSON FK. (1993). Inhibition of the multidrug resistance efflux pump. Biochim. Biophys. Acta., 1154, 173-181.